Tine Kold Olesen

MSc, Exec. MBA

Role in PharmNovo: Business advisor.

Born: 1963.

Education: MSc in Pharmacy from Copenhagen University in 1992, DK; Exec. MBA from Imperial College, London, UK in 2012.

Work experience: Tine is currently based in US and has 25 years of experience in pharmaceutical industry. She has worked at Ferring Pharmaceuticals in US and in Denmark for the past 18 years where she directs integrated clinical development programs from early stage to life cycle management in uro-/oncology with responsibility for the design and development of novel strategies from early stage and through marketing authorization, followed by market access in R&D. Her key focus is within CMC and clinical development, directing regulatory actions, including NDA submissions and FDA advisory committee, interpretation of scientific data, building the value story and development of new businesses. Tine has prior experience in the therapeutic fields of Parkinson’s disease, epilepsy, diabetes, and migraine headaches within large pharma companies (Novo, GSK, and Orion).

Member of:

Business advisors

Latest news

View all

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Meet Bengt von Mentzer, founder and Chief scientific advisor

March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Meet Olof Breuer, MD, Clinical pharmacology lead

January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.